A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
Part of paid clinical trials in San Francisco, California.
- Sponsor
- California Pacific Medical Center Research Institute
- Study ID
- NCT00259805
- Phase
- PHASE1
- Status
- Completed
Conditions
- Chronic Focal Encephalitis
- Rasmussen's Encephalitis
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 25 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG375 mg/m2 given as an IV infusion once weekly for four doses
Study Details
The purpose of this study is to assess the safety, tolerability and effectiveness of rituximab in the treatment of chronic focal encephalitis.
Key Dates
- Start date
- Jan 31, 2005
- Status verified
- Mar 2008
- Primary completion
- Dec 31, 2008
- Completion
- Dec 31, 2008
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: IV Infusion
Primary Outcome Measure
To assess the safety and tolerability of Rituximab in the treatment of CFE. Adverse and serious adverse events during the study period, reasonably or probably related to Rituximab, will be assessed at each study visit up to 12 months. [ Time Frame: 12 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| California Pacific Medical Center | San Francisco | California | 94115 | - |
Find similar trials in San Francisco, CA
By research site